Express Scripts Drug Information & Wellness Center Drug Information Updates
... NSAIDs act by preventing the formation of prostaglandins produced in response to painful stimuli which decreases the number of pain impulses received by the CNS.1 Prostaglandins within the kidneys help to diminish vascular resistance, dilate renal vascular beds and enhance organ perfusion. If this p ...
... NSAIDs act by preventing the formation of prostaglandins produced in response to painful stimuli which decreases the number of pain impulses received by the CNS.1 Prostaglandins within the kidneys help to diminish vascular resistance, dilate renal vascular beds and enhance organ perfusion. If this p ...
Treatment of Hypersexuality Patients
... Caution: with depression, diabetes, or conditions which may be worsened by fluid retention SE: weight gain, lethargy, headache, decreased sperm production, hot & cold flashes, hepatic dysfunction, nightmares, dyspnea, loss of body hair, hyperglycemia, leg cramps, GI disturbances, fluid retention, me ...
... Caution: with depression, diabetes, or conditions which may be worsened by fluid retention SE: weight gain, lethargy, headache, decreased sperm production, hot & cold flashes, hepatic dysfunction, nightmares, dyspnea, loss of body hair, hyperglycemia, leg cramps, GI disturbances, fluid retention, me ...
Instructions for the Medical Use of Arbidol
... fight infection. It decreases the frequency of complications associated with viral infections, and lessens the effects of chronic bacterial illnesses. In viral infections, its therapeutic effectiveness is seen in a lowering of toxicity, lessening of clinical symptoms, and decrease in duration of the ...
... fight infection. It decreases the frequency of complications associated with viral infections, and lessens the effects of chronic bacterial illnesses. In viral infections, its therapeutic effectiveness is seen in a lowering of toxicity, lessening of clinical symptoms, and decrease in duration of the ...
Pediatric Dosage Calculation Tutorial
... 8. The physician orders Prostigmin (neostigmine bromide) 8 mg q 4 hrs The drug guide recommended dosage is 2-4 mg/kg/day in divided doses Patients weight: 21 lbs Is the physicians order safe? ...
... 8. The physician orders Prostigmin (neostigmine bromide) 8 mg q 4 hrs The drug guide recommended dosage is 2-4 mg/kg/day in divided doses Patients weight: 21 lbs Is the physicians order safe? ...
ponstan capsules
... Diarrhoea may occur within 24 hours following usual analgesic dosage. When diarrhoea occurs, the medication should be discontinued immediately. Temporary lowering of the white blood cell count has occurred but does not appear to be dose-related. Blood counts should be performed at regular intervals ...
... Diarrhoea may occur within 24 hours following usual analgesic dosage. When diarrhoea occurs, the medication should be discontinued immediately. Temporary lowering of the white blood cell count has occurred but does not appear to be dose-related. Blood counts should be performed at regular intervals ...
Antibiotics Workshop
... – E.g. resistant strains of E.coli, S. aureus and H. influenzae. – Clavulanic acid has no antibacterial activity ...
... – E.g. resistant strains of E.coli, S. aureus and H. influenzae. – Clavulanic acid has no antibacterial activity ...
summary of product characteristics 1. name of the medicinal
... Pharmacokinetic Properties Atenolol Absorption of atenolol following oral dosing is consistent but incomplete (approximately 40-50%) with peak plasma concentrations occurring at 2-4 hours after dosing. The atenolol blood levels are consistent and subject to little variability. There is no significan ...
... Pharmacokinetic Properties Atenolol Absorption of atenolol following oral dosing is consistent but incomplete (approximately 40-50%) with peak plasma concentrations occurring at 2-4 hours after dosing. The atenolol blood levels are consistent and subject to little variability. There is no significan ...
~ T Lupin Pharmaceutials,kc .
... require drug firms to study certain drugs in pediatric patients if the agency felt that such study would provide beneficial health data for that patient population . The act also provided a provision for a waiver from such requirement if: (iii) the drug or biological product- ...
... require drug firms to study certain drugs in pediatric patients if the agency felt that such study would provide beneficial health data for that patient population . The act also provided a provision for a waiver from such requirement if: (iii) the drug or biological product- ...
Popular Links
... drug works for additional types of patients/diseases beyond the original use for which the drug was approved for marketing. - It is typically expected that there be at least two successful Phase III trials, demonstrating a drug's safety and efficacy in order to obtain approval from the FDA. Phase IV ...
... drug works for additional types of patients/diseases beyond the original use for which the drug was approved for marketing. - It is typically expected that there be at least two successful Phase III trials, demonstrating a drug's safety and efficacy in order to obtain approval from the FDA. Phase IV ...
local anesthetic agents
... sensitive or resistant to certain test antibiotics assists in determining which antibiotic to use in difficult infections. One to two days are required before the results of the test are available. Although antibiotic therapy can start before this time, it may be changed after the results are availa ...
... sensitive or resistant to certain test antibiotics assists in determining which antibiotic to use in difficult infections. One to two days are required before the results of the test are available. Although antibiotic therapy can start before this time, it may be changed after the results are availa ...
Full Prescribing Information
... HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ. BELEODAQ® (belinostat) for injection, for intravenous administration Initial U.S. Approval: 2014 ------------------- ...
... HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ. BELEODAQ® (belinostat) for injection, for intravenous administration Initial U.S. Approval: 2014 ------------------- ...
Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc.
... caused embryo-fetal death in animals. Women of childbearing potential should avoid becoming pregnant while being treated with Marqibo. There are no adequate and well-controlled studies of Marqibo in pregnant women and there were no reports of pregnancy in any of the clinical studies in the Marqibo c ...
... caused embryo-fetal death in animals. Women of childbearing potential should avoid becoming pregnant while being treated with Marqibo. There are no adequate and well-controlled studies of Marqibo in pregnant women and there were no reports of pregnancy in any of the clinical studies in the Marqibo c ...
NEWS YOU CAN USE 2015 12 UPD
... bolus plus two hour infusion • Reversal occurred in 94% of apixaban patients and 92% of rivaroxaban patients • No serious adverse events reported 11/11/2015 N Engl J Med ...
... bolus plus two hour infusion • Reversal occurred in 94% of apixaban patients and 92% of rivaroxaban patients • No serious adverse events reported 11/11/2015 N Engl J Med ...
click here to the doc
... established association of high cholesterol with dementia. However, it is known that cholesterol synthesis is necessary for normal neuron functioning. Elevation of alanine transaminase (ALT) and aspartate transaminase (AST) has been described in a few cases Drug and food interactions Interactions wi ...
... established association of high cholesterol with dementia. However, it is known that cholesterol synthesis is necessary for normal neuron functioning. Elevation of alanine transaminase (ALT) and aspartate transaminase (AST) has been described in a few cases Drug and food interactions Interactions wi ...
Sedation and Analgesia in the PCCU: General Principles
... Because of its slow onset of action, chloral hydrate should be given regularly, not on an as needed basis. Adverse effects include bradycardia, arrhythmias and accumulation with prolonged use. ...
... Because of its slow onset of action, chloral hydrate should be given regularly, not on an as needed basis. Adverse effects include bradycardia, arrhythmias and accumulation with prolonged use. ...
ProSom (estazolam)
... of insomnia. Similar to other benzodiazepines, ProSom has anxiolytic effects (i.e., relieves anxiety), but it is seldom prescribed for this use. It has an intermediate duration of action (i.e., half-life around 16 hours) and no active metabolite. For some patients, a single bedtime dose may lead to ...
... of insomnia. Similar to other benzodiazepines, ProSom has anxiolytic effects (i.e., relieves anxiety), but it is seldom prescribed for this use. It has an intermediate duration of action (i.e., half-life around 16 hours) and no active metabolite. For some patients, a single bedtime dose may lead to ...
Tuberculosis - ichapps.com
... a prognostic factor because it is frequently associated with Isoniazid resistance and leaves the patient with few good therapeutic options. Rifampin also is active against a broad array of other bacteria. Alteration of the target site on RNA polymerase, primarily through changes in the rpoB gene, le ...
... a prognostic factor because it is frequently associated with Isoniazid resistance and leaves the patient with few good therapeutic options. Rifampin also is active against a broad array of other bacteria. Alteration of the target site on RNA polymerase, primarily through changes in the rpoB gene, le ...
MULTAQ Dosing Card
... MULTAQ is contraindicated in patients with NYHA Class IV heart failure or symptomatic heart failure with recent decompensation requiring hospitalization because it doubles the risk of death. Cardiovascular Death and Heart Failure in Permanent AFib MULTAQ doubles the risk of cardiovascular death (lar ...
... MULTAQ is contraindicated in patients with NYHA Class IV heart failure or symptomatic heart failure with recent decompensation requiring hospitalization because it doubles the risk of death. Cardiovascular Death and Heart Failure in Permanent AFib MULTAQ doubles the risk of cardiovascular death (lar ...
Product Information – Australia Chemmart Bisoprolol Tablets Page 1
... Use with caution in the following circumstances The initiation of treatment with bisoprolol necessitates regular monitoring. There is no therapeutic experience of bisoprolol treatment of heart failure in patients with the following diseases and conditions: insulin dependent diabetes mellitus (type 1 ...
... Use with caution in the following circumstances The initiation of treatment with bisoprolol necessitates regular monitoring. There is no therapeutic experience of bisoprolol treatment of heart failure in patients with the following diseases and conditions: insulin dependent diabetes mellitus (type 1 ...
Click here
... – Most likely in susceptible patients – Pathogenesis is unrelated to known mechanism of drug – Results from abnormal immunological reaction – May be more than one mechanism ...
... – Most likely in susceptible patients – Pathogenesis is unrelated to known mechanism of drug – Results from abnormal immunological reaction – May be more than one mechanism ...
... liver parenchymal damage, blood dyscrasia, severe renal insufficiency, glucose 6-phosphate dehydrogenase deficiency. Pregnancy and Lactation : Although Co-trimoxazole has been used during pregnancy without deleterious sequelae, animal studies have indicated a risk of teratogenic effects. Co-trimoxaz ...
Stage-Specific Treatment of Malaria
... forms of P.falciparum including strains resistant to chloroquine, mefloquine and pyrimethamine/sulfadoxine (not active vs hepatic stages). ...
... forms of P.falciparum including strains resistant to chloroquine, mefloquine and pyrimethamine/sulfadoxine (not active vs hepatic stages). ...
Grapefruit to Glaucoma
... limiting the use of the highest approved dose of the cholesterollowering medication simvastatin (80 mg) because of increased risk of muscle damage. Patients taking simvastatin 80 mg daily have an increased risk of myopathy compared to patients taking lower doses of this drug or other drugs in the sa ...
... limiting the use of the highest approved dose of the cholesterollowering medication simvastatin (80 mg) because of increased risk of muscle damage. Patients taking simvastatin 80 mg daily have an increased risk of myopathy compared to patients taking lower doses of this drug or other drugs in the sa ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.